WO2010110545A2 - 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 - Google Patents

신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
WO2010110545A2
WO2010110545A2 PCT/KR2010/001656 KR2010001656W WO2010110545A2 WO 2010110545 A2 WO2010110545 A2 WO 2010110545A2 KR 2010001656 W KR2010001656 W KR 2010001656W WO 2010110545 A2 WO2010110545 A2 WO 2010110545A2
Authority
WO
WIPO (PCT)
Prior art keywords
same
pharmaceutical composition
hydroxamate derivative
production method
derivative
Prior art date
Application number
PCT/KR2010/001656
Other languages
English (en)
French (fr)
Other versions
WO2010110545A3 (ko
Inventor
이성숙
이경주
이창식
양현모
김도훈
최대규
최호진
김달현
황인창
김미정
한병훈
Original Assignee
주식회사종근당
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사종근당 filed Critical 주식회사종근당
Priority to BRPI1007092A priority Critical patent/BRPI1007092B8/pt
Priority to EP10756300.9A priority patent/EP2412706B1/en
Priority to CN201080013979.6A priority patent/CN102365270B/zh
Priority to AU2010229591A priority patent/AU2010229591B2/en
Priority to ES10756300.9T priority patent/ES2525566T3/es
Priority to MX2011010065A priority patent/MX2011010065A/es
Priority to US13/258,630 priority patent/US8466161B2/en
Priority to CA2754085A priority patent/CA2754085C/en
Priority to JP2012501923A priority patent/JP5555868B2/ja
Publication of WO2010110545A2 publication Critical patent/WO2010110545A2/ko
Publication of WO2010110545A3 publication Critical patent/WO2010110545A3/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

본 발명은 하이드록사메이트 유도체, 이의 이성질체, 약제학적으로 허용가능한 이들의 염, 이들의 수화물 또는 이들의 용매화물, 약제학적 조성물을 제조하기 위한 이들의 용도, 이들을 함유하는 약제학적 조성물과 상기 조성물을 이용한 질병의 예방 또는 치료방법, 및 상기 하이드록사메이트 유도체의 제조방법에 관한 것이다.
PCT/KR2010/001656 2009-03-27 2010-03-18 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 WO2010110545A2 (ko)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI1007092A BRPI1007092B8 (pt) 2009-03-27 2010-03-18 Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato
EP10756300.9A EP2412706B1 (en) 2009-03-27 2010-03-18 Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
CN201080013979.6A CN102365270B (zh) 2009-03-27 2010-03-18 新的氧肟酸衍生物、其制备方法以及包含它的药物组合物
AU2010229591A AU2010229591B2 (en) 2009-03-27 2010-03-18 Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
ES10756300.9T ES2525566T3 (es) 2009-03-27 2010-03-18 Nuevo derivado de hidroxamato, método para producirlo y composición farmacéutica que lo contiene
MX2011010065A MX2011010065A (es) 2009-03-27 2010-03-18 Novedoso derivado de hidroxamato, un metodo de produccion del mismo y una composicion farmaceutica que comprende el mismo.
US13/258,630 US8466161B2 (en) 2009-03-27 2010-03-18 Hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
CA2754085A CA2754085C (en) 2009-03-27 2010-03-18 Novel hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same
JP2012501923A JP5555868B2 (ja) 2009-03-27 2010-03-18 新規なヒドロキサメート誘導体、その作製方法、及びこれを含有する薬学的組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090026578 2009-03-27
KR10-2009-0026578 2009-03-27

Publications (2)

Publication Number Publication Date
WO2010110545A2 true WO2010110545A2 (ko) 2010-09-30
WO2010110545A3 WO2010110545A3 (ko) 2011-03-24

Family

ID=42781631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001656 WO2010110545A2 (ko) 2009-03-27 2010-03-18 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물

Country Status (11)

Country Link
US (1) US8466161B2 (ko)
EP (1) EP2412706B1 (ko)
JP (1) JP5555868B2 (ko)
KR (1) KR101168801B1 (ko)
CN (1) CN102365270B (ko)
AU (1) AU2010229591B2 (ko)
BR (1) BRPI1007092B8 (ko)
CA (1) CA2754085C (ko)
ES (1) ES2525566T3 (ko)
MX (1) MX2011010065A (ko)
WO (1) WO2010110545A2 (ko)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771321A1 (en) * 2011-10-28 2014-09-03 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
WO2018066946A1 (en) 2016-10-04 2018-04-12 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer
WO2018102261A3 (en) * 2016-11-29 2018-11-01 Xavier University Of Louisiana Boronic derivatives hydroxamates as anticancer agents
US11420950B2 (en) 2015-05-22 2022-08-23 Chong Kun Dang Pharmaceutical Corp. Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2684396T3 (es) * 2012-08-31 2018-10-02 Novadrug, Llc Heterociclil carboxamidas para tratar enfermedades víricas
US9878986B2 (en) * 2013-04-29 2018-01-30 Chong Kun Dang Pharmaceutical Corp. Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
TR201900057T4 (tr) 2013-12-12 2019-01-21 Chong Kun Dang Pharmaceutical Corp Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler.
RU2016148863A (ru) * 2014-05-14 2018-06-18 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт Гетероциклические гидроксамовые кислоты в качестве ингибиторов протеин-деацетилазы и двойных ингибиторов протеин-деацетилазы-протеин-киназы и способы их применения
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
KR102236356B1 (ko) * 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
CN109096272B (zh) * 2018-09-27 2021-04-02 沈阳药科大学 一种具有抗肿瘤活性的吲哚异羟肟酸类化合物及其应用
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771760A (en) 1902-07-12 1904-10-04 David M Balch Process of treating seaweed.
EP0847992A1 (en) 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2004069823A1 (en) 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7135493B2 (en) * 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
WO2004110989A1 (en) * 2003-05-14 2004-12-23 Bayer Pharmaceuticals Corporation N-hydroxy-7-(arylamino)heptanamide derivatives useful for treating hyper-proliferative disorders
EP1937650B1 (en) * 2005-09-08 2011-06-15 S*BIO Pte Ltd Heterocyclic compounds
KR20090077914A (ko) * 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
KR100814098B1 (ko) * 2006-11-03 2008-03-14 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 알킬아미노나프탈렌일옥시 메틸옥트 n-하이드록시엔아마이드 유도체,이의 제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물
WO2009002534A1 (en) * 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771760A (en) 1902-07-12 1904-10-04 David M Balch Process of treating seaweed.
EP0847992A1 (en) 1996-09-30 1998-06-17 Mitsui Chemicals, Inc. Benzamide derivatives, useful as cell differentiation inducers
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2004069823A1 (en) 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 66, 2006, pages 5781 - 5789
GABBIANELLI. M. ET AL., BLOOD, vol. 95, 2000, pages 3555 - 3561
INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 33, 2008, pages 637 - 646
JOHNSTONE. R.W, NAT. REV. DRUG DISCOV., vol. 1, 2002, pages 287 - 299
LI. S. ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 7803 - 7815
MARKS ET AL., NATURE REVIEWS, vol. 1, 2001, pages 194 - 202
MARKS, P.A ET AL., CURR OPIN. ONCOL., vol. 13, 2001, pages 477 - 483
MOL CANCER RES, vol. 5, 2007, pages 981
MORRIS, G. A. ET AL., TETRAHEDRON LETT., vol. 42, 2001, pages 2093
See also references of EP2412706A4
STEFFAN, J. S. ET AL., NATURE, vol. 413, 2001, pages 739 - 743

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771321A1 (en) * 2011-10-28 2014-09-03 Chong Kun Dang Pharmaceutical Corp. Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
EP2771321A4 (en) * 2011-10-28 2015-04-08 Chong Kun Dang Pharm Corp HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
US11420950B2 (en) 2015-05-22 2022-08-23 Chong Kun Dang Pharmaceutical Corp. Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
WO2018066946A1 (en) 2016-10-04 2018-04-12 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer
WO2018102261A3 (en) * 2016-11-29 2018-11-01 Xavier University Of Louisiana Boronic derivatives hydroxamates as anticancer agents
US11046715B2 (en) 2016-11-29 2021-06-29 Xavier University Of Louisiana Boronic derivatives of hydroxamates as anticancer agents

Also Published As

Publication number Publication date
CN102365270B (zh) 2014-07-30
ES2525566T3 (es) 2014-12-26
BRPI1007092B8 (pt) 2022-07-26
EP2412706A2 (en) 2012-02-01
EP2412706B1 (en) 2014-10-29
MX2011010065A (es) 2011-10-10
EP2412706A4 (en) 2012-05-09
US20120028963A1 (en) 2012-02-02
KR101168801B1 (ko) 2012-07-25
JP2012521982A (ja) 2012-09-20
AU2010229591B2 (en) 2013-01-31
KR20100108220A (ko) 2010-10-06
AU2010229591A1 (en) 2011-10-20
US8466161B2 (en) 2013-06-18
CN102365270A (zh) 2012-02-29
JP5555868B2 (ja) 2014-07-23
BRPI1007092B1 (pt) 2022-07-12
BRPI1007092A2 (pt) 2015-08-18
WO2010110545A3 (ko) 2011-03-24
CA2754085A1 (en) 2010-09-30
CA2754085C (en) 2014-03-18

Similar Documents

Publication Publication Date Title
WO2010110545A2 (ko) 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2010108074A3 (en) Inhibitors of pi3 kinase
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
AU2012214029A8 (en) Rorgammat inhibitors
IN2012DN00639A (ko)
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
WO2012071509A3 (en) Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
IN2014KN00948A (ko)
MX2012004780A (es) Inhibidores de akt.
GEP20125708B (en) Hydroxamate-based inhibitors of deacetylases b
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
TN2012000458A1 (en) Uses of dgat1 inhibitors
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
WO2011028044A3 (ko) 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
WO2011028043A3 (ko) 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
WO2009140341A3 (en) Atorvastatin compositions
AU2012277905A8 (en) Topical ophthalmological pharmaceutical composition containing regorafenib

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080013979.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10756300

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2754085

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010756300

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6989/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010229591

Country of ref document: AU

Ref document number: 13258630

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012501923

Country of ref document: JP

Ref document number: MX/A/2011/010065

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010229591

Country of ref document: AU

Date of ref document: 20100318

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1007092

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1007092

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110927